Biodexa (BDRX) Fundamental Analysis: Revenue, Earnings & Valuation

1.88 / 10

Underperform

The company posted a £6.38 M net loss in 2025 with zero revenue and £8.53 M cash, extending runway to Q3 2026 via a $35 M credit line. High current‑liabilities ratio (85.7%) and negative interest coverage (-19.6) drive an Underperform rating.

Analysis Checks(6/7)

Total operating revenue (YoY growth rate %)

Value-36.32

Score2/3

Weight-3.50%

1M Return0.13%

Inventory turnover ratio

Value20.64

Score2/3

Weight29.06%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value85.73

Score1/3

Weight40.67%

1M Return-1.69%

Long-term debt to working capital ratio (%)

Value0.08

Score3/3

Weight-22.29%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value-19.59

Score2/3

Weight29.55%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-36.32

Score2/3

Weight-1.42%

1M Return0.05%

Cost of sales ratio (%)

Value71.22

Score2/3

Weight27.93%

1M Return-1.13%

Is BDRX undervalued or overvalued?

BDRX scores 1.88/10 on fundamentals and holds a Premium valuation at present. Backed by its -64.72% ROE, 0.00% net margin, -0.33 P/E ratio, 0.18 P/B ratio, and 89.26% earnings growth, these metrics solidify its Underperform investment rating.